Press Releases
Endonovo Therapeutics Announces Issuance of U.S. Patent Covering Apparatus and Method for Electromagnetic Treatment of Neurological Injury or Condition Caused by a Stroke
Issuance of U.S. Patent No. 15217855 Further Bolsters Endonovo’s Intellectual Patent Portfolio
Los Angeles, CA, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDVD / ENDV) ("Endonovo" or the "Company"
, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 15217855, which is directed to the usage of an Apparatus and Method for Electromagnetic Treatment of Neurological Injury or Condition Caused by a Stroke.
Alan Collier, CEO of Endonovo Therapeutics stated, “We are extremely pleased with the continued development and expansion of our patent portfolio. This new issuance continues to expand the breadth and depth of our SofPulse® unit intellectual property portfolio and the issuance of this patent is another step in the development of a robust patent portfolio relating to SofPulse®.”
Dr. Nev Zubcevik, Endonovo’s Chief Medical Officer and Harvard trained Physical Medicine and Rehabilitation specialist, stated, “Endonovo’s Electroceuticals® are electronic devices designed to improve healing by mitigating underlying etiology of inflammation and swelling in tissues. Pulsed Electromagnetic Field-based (PEMF) Electroceuticals® which use a unique electromagnetic field to deliver stimulation to tissues via induction, function by accelerating the production of the endogenous constitutive nitric oxide synthesis, improving anti-inflammatory mechanisms. Our published data in the Journal of Translational Stroke Research by the team at the University of New Mexico Health Sciences Center shows significant reduction of ischemic infarct size in PEMF-treated animals as compared to controls as seen on MRI. In addition, neuroinflammation, evaluated by using specialized cytokine/chemokine PCR array demonstrated that the SofPulse® PEMF significantly reduced gene expression encoding for the major pro-inflammatory cytokine IL-1α, while expression of major anti-inflammatory IL-10 was significantly increased. Every year, more than 795,000 people in the United States have a stroke. About 87% of all strokes are ischemic strokes. We are thrilled to the future potential the SofPulse® may have by reducing the burden of ischemic strokes and improving outcomes.
In management’s opinion, this patent provides important coverage for SofPulse® as we continue to address the tremendous patient needs that exist.”
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals® therapeutic devices. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals® therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical® therapeutic device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticals® therapeutic devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company's non-invasive, wearable Electroceuticals® therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. www.endonovo.com
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Andrew Barwicki
516-662-9461
Andrew@barwicki.com
www.endonovo.com
Primary Logo
Source: Endonovo Therapeutics, Inc.
Released January 7, 2020
Endonovo Therapeutics Announces Issuance of U.S. Patent Covering Apparatus and Method for Electromagnetic Treatment of Neurological Injury or Condition Caused by a Stroke
Issuance of U.S. Patent No. 15217855 Further Bolsters Endonovo’s Intellectual Patent Portfolio
Los Angeles, CA, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDVD / ENDV) ("Endonovo" or the "Company"
, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 15217855, which is directed to the usage of an Apparatus and Method for Electromagnetic Treatment of Neurological Injury or Condition Caused by a Stroke. Alan Collier, CEO of Endonovo Therapeutics stated, “We are extremely pleased with the continued development and expansion of our patent portfolio. This new issuance continues to expand the breadth and depth of our SofPulse® unit intellectual property portfolio and the issuance of this patent is another step in the development of a robust patent portfolio relating to SofPulse®.”
Dr. Nev Zubcevik, Endonovo’s Chief Medical Officer and Harvard trained Physical Medicine and Rehabilitation specialist, stated, “Endonovo’s Electroceuticals® are electronic devices designed to improve healing by mitigating underlying etiology of inflammation and swelling in tissues. Pulsed Electromagnetic Field-based (PEMF) Electroceuticals® which use a unique electromagnetic field to deliver stimulation to tissues via induction, function by accelerating the production of the endogenous constitutive nitric oxide synthesis, improving anti-inflammatory mechanisms. Our published data in the Journal of Translational Stroke Research by the team at the University of New Mexico Health Sciences Center shows significant reduction of ischemic infarct size in PEMF-treated animals as compared to controls as seen on MRI. In addition, neuroinflammation, evaluated by using specialized cytokine/chemokine PCR array demonstrated that the SofPulse® PEMF significantly reduced gene expression encoding for the major pro-inflammatory cytokine IL-1α, while expression of major anti-inflammatory IL-10 was significantly increased. Every year, more than 795,000 people in the United States have a stroke. About 87% of all strokes are ischemic strokes. We are thrilled to the future potential the SofPulse® may have by reducing the burden of ischemic strokes and improving outcomes.
In management’s opinion, this patent provides important coverage for SofPulse® as we continue to address the tremendous patient needs that exist.”
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals® therapeutic devices. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals® therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical® therapeutic device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticals® therapeutic devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company's non-invasive, wearable Electroceuticals® therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. www.endonovo.com
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Andrew Barwicki
516-662-9461
Andrew@barwicki.com
www.endonovo.com
Primary Logo
Source: Endonovo Therapeutics, Inc.
Released January 7, 2020
